Matches in SemOpenAlex for { <https://semopenalex.org/work/W2224492717> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2224492717 endingPage "1094" @default.
- W2224492717 startingPage "1094" @default.
- W2224492717 abstract "1094 Background: There is increasing evidence that women with HER2-positive metastatic breast cancer (MBC) benefit from continued trastuzumab (H) therapy beyond disease progression (PD). In a Phase II multicentre 2-step trial we evaluated women for their response to second-line treatment with H + vinorelbine (N) following PD after receiving first-line H + taxane for HER2-positive MBC. Methods: Women aged =18 years with HER2-positive MBC received H (8 mg/kg loading dose followed by 6 mg/kg q3w or 4 mg/kg loading dose followed by 2 mg/kg qw) + N (30 mg/m 2 days 1 and 8 q3w) until PD. The primary end point was overall response rate (ORR); secondary end points included time to progression, time to treatment failure, overall survival and safety. Data from a planned interim analysis are presented. Results: Seventeen out of a planned 50 patients (pts) were enrolled between June 2003 and October 2006, with a mean age of 54 years (range 42–70). Nine pts had hormone receptor-positive disease at baseline and 17 pts had HER2-positive disease (16 pts IHC 3+; 1 pt IHC 2+ and CISH+). Pts had previously received H in combination with paclitaxel (9 pts) or docetaxel (8 pts) as first-line therapy for MBC. Pts received a median of 6 treatment cycles with H + N (range 2–14), with 2 pts receiving H q3w and 15 pts receiving H qw. ORR was 29%, with 2 pts showing a complete response, 3 pts experiencing a partial response and 4 pts achieving stable disease lasting 6 months. Eight pts experienced PD. Re-treatment with H + N was well tolerated beyond PD, with grade 3/4 haematological toxicities being the most common serious adverse events, leading to a delay and dose reduction of N. No relevant cardiac toxicities were reported, with only 2 grade 1 cardiac events. All pts withdrew, 14 due to PD. Conclusions: This interim analysis indicates that treatment with Herceptin plus chemotherapy beyond PD is active (ORR 29%) and well tolerated, and provides further evidence that re-treatment with H is a promising therapeutic option. Pt accrual is ongoing and updated results will be presented. No significant financial relationships to disclose." @default.
- W2224492717 created "2016-06-24" @default.
- W2224492717 creator A5000010493 @default.
- W2224492717 creator A5006109406 @default.
- W2224492717 creator A5006220690 @default.
- W2224492717 creator A5015900909 @default.
- W2224492717 creator A5041410352 @default.
- W2224492717 creator A5077857574 @default.
- W2224492717 creator A5086724383 @default.
- W2224492717 creator A5018360318 @default.
- W2224492717 date "2007-06-20" @default.
- W2224492717 modified "2023-10-17" @default.
- W2224492717 title "Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression" @default.
- W2224492717 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.1094" @default.
- W2224492717 hasPublicationYear "2007" @default.
- W2224492717 type Work @default.
- W2224492717 sameAs 2224492717 @default.
- W2224492717 citedByCount "4" @default.
- W2224492717 crossrefType "journal-article" @default.
- W2224492717 hasAuthorship W2224492717A5000010493 @default.
- W2224492717 hasAuthorship W2224492717A5006109406 @default.
- W2224492717 hasAuthorship W2224492717A5006220690 @default.
- W2224492717 hasAuthorship W2224492717A5015900909 @default.
- W2224492717 hasAuthorship W2224492717A5018360318 @default.
- W2224492717 hasAuthorship W2224492717A5041410352 @default.
- W2224492717 hasAuthorship W2224492717A5077857574 @default.
- W2224492717 hasAuthorship W2224492717A5086724383 @default.
- W2224492717 hasConcept C121608353 @default.
- W2224492717 hasConcept C126322002 @default.
- W2224492717 hasConcept C141071460 @default.
- W2224492717 hasConcept C143998085 @default.
- W2224492717 hasConcept C203092338 @default.
- W2224492717 hasConcept C2775930923 @default.
- W2224492717 hasConcept C2776694085 @default.
- W2224492717 hasConcept C2777511904 @default.
- W2224492717 hasConcept C2778239845 @default.
- W2224492717 hasConcept C2779786085 @default.
- W2224492717 hasConcept C2780350996 @default.
- W2224492717 hasConcept C2781190966 @default.
- W2224492717 hasConcept C530470458 @default.
- W2224492717 hasConcept C535046627 @default.
- W2224492717 hasConcept C71924100 @default.
- W2224492717 hasConceptScore W2224492717C121608353 @default.
- W2224492717 hasConceptScore W2224492717C126322002 @default.
- W2224492717 hasConceptScore W2224492717C141071460 @default.
- W2224492717 hasConceptScore W2224492717C143998085 @default.
- W2224492717 hasConceptScore W2224492717C203092338 @default.
- W2224492717 hasConceptScore W2224492717C2775930923 @default.
- W2224492717 hasConceptScore W2224492717C2776694085 @default.
- W2224492717 hasConceptScore W2224492717C2777511904 @default.
- W2224492717 hasConceptScore W2224492717C2778239845 @default.
- W2224492717 hasConceptScore W2224492717C2779786085 @default.
- W2224492717 hasConceptScore W2224492717C2780350996 @default.
- W2224492717 hasConceptScore W2224492717C2781190966 @default.
- W2224492717 hasConceptScore W2224492717C530470458 @default.
- W2224492717 hasConceptScore W2224492717C535046627 @default.
- W2224492717 hasConceptScore W2224492717C71924100 @default.
- W2224492717 hasIssue "18_suppl" @default.
- W2224492717 hasLocation W22244927171 @default.
- W2224492717 hasOpenAccess W2224492717 @default.
- W2224492717 hasPrimaryLocation W22244927171 @default.
- W2224492717 hasRelatedWork W1971716849 @default.
- W2224492717 hasRelatedWork W2029620489 @default.
- W2224492717 hasRelatedWork W2050605839 @default.
- W2224492717 hasRelatedWork W2107960402 @default.
- W2224492717 hasRelatedWork W2147874203 @default.
- W2224492717 hasRelatedWork W2163622510 @default.
- W2224492717 hasRelatedWork W3013506684 @default.
- W2224492717 hasRelatedWork W4246454966 @default.
- W2224492717 hasRelatedWork W4249932378 @default.
- W2224492717 hasRelatedWork W4300176258 @default.
- W2224492717 hasVolume "25" @default.
- W2224492717 isParatext "false" @default.
- W2224492717 isRetracted "false" @default.
- W2224492717 magId "2224492717" @default.
- W2224492717 workType "article" @default.